Immuno-Oncology

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. (2019) Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO , Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC The Journal of Clinical Investigation

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors (2019) Piha-Paul SA, Hann CL, French CA, Cousin S, Brana I, Cassier PA, Moreno V, de Bono JS, Duckworth Harward S, Ferron-Brady G, Barbash O, Wyce A, Wu Y, Horner T, Annan M, Parr NJ, Prinjha RK, Carpenter CL, Hilton J, Hong DS, Hass NB, Markowski MC, Dhar A, O'Dwyer PJ, Shapiro GI JNCI Cancer Spectrum

A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. (2019) Rammensee HG, Wiesmuller KH, Chandran PA, Zelba H, Rusch E, Gouttefangeas C, Kowalewski DJ, Di Marco M, Haen SP, Walz JS, Gloria YC, Bodder J, Schertel JM, Tunger A, Muller L, Kiebler M, Wehner R, Schmitz M, Jakobi M, Schneiderhan-Marra N, Klein R, Laske K, Artzner K, Backert L, Schuster H, Schwenck J, Weber ANR, Pichler BJ, Kneilling M, la Fougere C, Forchhammer S, Metzler G, Bauer J, Weide B, Schippert W, Stevanovic S, Loffler MW Journal for ImmunoTherapy of Cancer

Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma. (2019) Wang R, Zheng J, Shao X, Ishii Y, Roy A, Bello A, Lee R, Zhang J, Wind-Rotolo M, Feny Y Journal for ImmunoTherapy of Cancer

Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease (2018) Gu JM, Yuam S, Sim D, Abe K, Liu P, Rosenbruch M, Bringmann P, Kauser K Experimental Hematology 2018

Standardized Immunomonitoring: Separating the Signals from the Noise (2018) Duffy D Trends in Biotechnology

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients (2018) Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Levegue J, Tannir NM, Oft M Cancer Cell

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (2017) Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM and Butterfield LH J Immunother Cancer

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles (2017) Loges S, Gjertsen BT, Heuser M, Chromik J, Ben-Batalla I, Akyuz N, Micklem D, Brown A, Lorens J, Yule M, Kebenko M, Janning M, Binder M, Fiedler W, Cortes J Blood

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) Choueiri TK, Fishman M, Escudier B, McDermott DF, Drake CG, Kluger HM, Stadler WM, Perez-Gracia JL, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Albiges L, Cohen LJ, Young TC, Chasalow SD, Ross-MacDonald P, Srivastava S, Jure-Kunkel M, Kurland JF, Simon JS, Sznol M Clinical Cancer Research

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (Am0010) in Patients with Advanced Solid Tumors (2016) Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR Journal of Clinical Oncology

Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) Sznol M, Fishman M, Escudier B, McDermott DF, Kluger H, Stadler WM, Perez-Gracia J, McNeel DG, Curti BD, Harrison MR, Plimack ER, Appleman L, Fong L, Drake CG, Young TC, Chasalow SD, Ross-MacDonald P, Simon JS, Walker D, Choueiri TK J Immunother Cancer

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. (2014) Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. Nature. 2014 Nov 26;515(7528):558-62. doi: 10.1038/nature13904.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. (2014) Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Nature. 2014 Nov 26;515(7528):563-7. doi: 10.1038/nature14011.